← Back to the Areas of Interest
Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
View the full invitation
Takeda - Oncogenic drivers in advanced NSCLC: Navigating an evolving landscape to optimize patient outcomes
MSD - Redefining survival expectations in NSCLC
Bristol Myers Squibb - Exploring the current and evolving landscape in thoracic cancers
AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
TouchIME - PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
Programme and Faculty are preliminary and subject to change.
© 2019 cSLIDE CTI MEETING TECHNOLOGY. All rights reserved.